Minimally invasive approach to the repair of injured skeletal muscle with a shape-memory scaffold

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1441-1449

  Wang, Lin ^a,b,c   Cao, Lan ^a   Shansky, Janet ^d   Wang, Zheng ^c   Mooney, David ^a   Vandenburgh, Herman ^a,b,d  

^a HARVARD UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Myomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; SHAPE MEMORY ALGINATE SCAFFOLD; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; ALGINIC ACID; GLUCURONIC ACID; HEXURONIC ACID; INSULIN-LIKE GROWTH FACTOR-1, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENGRAFTMENT; ENZYME RELEASE; IN VIVO STUDY; MALE; MINIMALLY INVASIVE SURGERY; MOUSE; MUSCLE CONTRACTION; MUSCLE INJURY; MUSCLE REGENERATION; MYOBLAST; NONHUMAN; SCAR FORMATION; TIBIALIS ANTERIOR MUSCLE; TRANSPLANTATION; ANIMAL; C3H MOUSE; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; INJURIES; METABOLISM; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SOFT TISSUE INJURIES; SURGERY; TISSUE SCAFFOLD; BIODEGRADABLE IMPLANT; MYOFIBROSIS; SHAPE MEMORY SCAFFOLD;

ALGINATES; ANIMALS; BIOCOMPATIBLE MATERIALS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLUCURONIC ACID; HEXURONIC ACIDS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, INBRED C3H; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; SOFT TISSUE INJURIES; TISSUE SCAFFOLDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905506350     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.78     Document Type: Article

References (49)

1. McClatchey, KD (2004). Musculoskeletal conditions affect millions. Arch Pathol Lab Med 128: 480.
2. Lubeck, DP (2003). The costs of musculoskeletal disease: health needs assessment and health economics. Best Pract Res Clin Rheumatol 17: 529-539.
3. Järvinen, M (1975). Healing of a crush injury in rat striated muscle. 2. a histological study of the effect of early mobilization and immobilization on the repair processes. Acta Pathol Microbiol Scand A 83: 269-282.
4. Järvinen, M (1976). Healing of a crush injury in rat striated muscle. 4. Effect of early mobilization and immobilization on the tensile properties of gastrocnemius muscle. Acta Chir Scand 142: 47-56.
5. Huard, J, Li, Y and Fu, FH (2002). Muscle injuries and repair: current trends in research. J Bone Joint Surg Am 84-A: 822-832.
6. Järvinen, TA, Järvinen, TL, Kääriäinen, M, Kalimo, H and Järvinen, M (2005). Muscle injuries: biology and treatment. Am J Sports Med 33: 745-764.
7. Järvinen, TA, Järvinen, TL, Kääriäinen, M, Aärimaa, V, Vaittinen, S, Kalimo, H et al. (2007). Muscle injuries: optimising recovery. Best Pract Res Clin Rheumatol 21: 317-331.
8. Gates, C and Huard, J (2005). Management of skeletal muscle injuries in military personnel. Oper Techn Sport Med 13: 247-256.
9. Skuk, D and Tremblay, JP (2003). Myoblast transplantation: the current status of a potential therapeutic tool for myopathies. J Muscle Res Cell Motil 24: 285-300.
10. Saxena, AK, Marler, J, Benvenuto, M, Willital, GH and Vacanti, JP (1999). Skeletal muscle tissue engineering using isolated myoblasts on synthetic biodegradable polymers: preliminary studies. Tissue Eng 5: 525-532.
11. Anastasi, S, Giordano, S, Sthandier, O, Gambarotta, G, Maione, R, Comoglio, P et al. (1997). A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. J Cell Biol 137: 1057-1068.
12. Beauchamp, JR, Morgan, JE, Pagel, CN and Partridge, TA (1999). Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 144: 1113-1122.
13. Koutsilieris, M, Philippou, A, Maridaki, M and Halapas, A (2007). The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 45-54.
14. Qu, Z, Balkir, L, van Deutekom, JC, Robbins, PD, Pruchnic, R and Huard, J (1998). Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 142: 1257-1267.
15. Langer, R and Vacanti, JP (1993). Tissue engineering. Science 260: 920-926.
16. Lanza, RP, Langer, RS and Vacanti, J (2007). Principles of Tissue Engineering, Elsevier/ Academic Press: Amsterdam; Boston.
17. Grefte, S, Kuijpers-Jagtman, AM, Toensma, R and Von den Hoff, JW (2007). Skeletal muscle development and regeneration. Stem Cells Dev 16: 857-868.
18. Philippou, A, Halapas, A, Maridaki, M and Koutsilieris, M (2007). Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 7: 208-218.
19. Coultas, L, Chawengsaksophak, K and Rossant, J (2005). Endothelial cells and VEGF in vascular development. Nature 438: 937-945.
20. Ferrara, N and Kerbel, RS (2005). Angiogenesis as a therapeutic target. Nature 438: 967-974.
21. Ferrara, N, Gerber, HP and LeCouter, J (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676.
22. Borselli, C, Storrie, H, Benesch-Lee, F, Shvartsman, D, Cezar, C, Lichtman, JW et al. (2010). Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci USA 107: 3287-3292.
23. Wang, L, Shansky, J, Borselli, C, Mooney, D and Vandenburgh, H (2012). Design and fabrication of a biodegradable, covalently crosslinked shape-memory alginate scaffold for cell and growth factor delivery. Tissue Eng Part A 18: 2000-2007.
24. Silva, EA and Mooney, DJ (2007). Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5: 590-598.
25. Silva, EA and Mooney, DJ (2010). Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31: 1235-1241.
26. Koning, M, Harmsen, MC, van Luyn, MJ and Werker, PM (2009). Current opportunities and challenges in skeletal muscle tissue engineering. J Tissue Eng Regen Med 3: 407-415.
27. Bencherif, SA, Sands, RW, Bhatta, D, Arany, P, Verbeke, CS, Edwards, DA et al. (2012). Injectable preformed scaffolds with shape-memory properties. Proc Natl Acad Sci USA 109: 19590-19595.
28. Borselli, C, Cezar, CA, Shvartsman, D, Vandenburgh, HH and Mooney, DJ (2011). The role of multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle regeneration. Biomaterials 32: 8905-8914.
29. Mourkioti, F and Rosenthal, N (2005). IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 26: 535-542.
30. Smythe, GM, Hodgetts, SI and Grounds, MD (2001). Problems and solutions in myoblast transfer therapy. J Cell Mol Med 5: 33-47.
31. Skuk, D, Caron, N, Goulet, M, Roy, B, Espinosa, F and Tremblay, JP (2002). Dynamics of the early immune cellular reactions after myogenic cell transplantation. Cell Transplant 11: 671-681.
32. Collins, CA, Olsen, I, Zammit, PS, Heslop, L, Petrie, A, Partridge, TA et al. (2005). Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 122: 289-301.
33. Boldrin, L, Elvassore, N, Malerba, A, Flaibani, M, Cimetta, E, Piccoli M et al. (2007). Satellite cells delivered by micro-patterned scaffolds: A new strategy for cell transplantation in muscle diseases. Tissue Eng 13: 253-262.
34. Hill, E, Boontheekul, T and Mooney, DJ (2006). Regulating activation of transplanted cells controls tissue regeneration. Proc Natl Acad Sci U S A 103: 2494-2499.
35. Wakelam, MJ (1985). The fusion of myoblasts. Biochem J 228: 1-12.
36. Chargé, SB and Rudnicki, MA (2004). Cellular and molecular regulation of muscle regeneration. Physiol Rev 84: 209-238.
37. Montarras, D, Morgan, J, Collins, C, Relaix, F, Zaffran, S, Cumano, A et al. (2005). Direct isolation of satellite cells for skeletal muscle regeneration. Science 309: 2064-2067.
38. Soulillou, JP and Giral, M (2001). Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 72(suppl. 12): S89-S93.
39. Morath, C, Mueller, M, Goldschmidt, H, Schwenger, V, Opelz, G and Zeier, M (2004). Malignancy in renal transplantation. J Am Soc Nephrol 15: 1582-1588.
40. Dixon, RW and Harris, JB (1996). Myotoxic activity of the toxic phospholipase, notexin, from the venom of the Australian tiger snake. J Neuropathol Exp Neurol 55: 1230-1237.
41. Gutiérrez, JM and Ownby, CL (2003). Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity. Toxicon 42: 915-931.
42. Kong, H, Lee, KY and Mooney, DJ (2002). Decoupling the dependence of rheological/ mechanical properties of hydrogels from solids concentration. Polymer 43: 6239-6246.
43. Boontheekul, T, Kong, HJ and Mooney, DJ (2005). Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26: 2455-2465.
44. Rowley, JA, Madlambayan, G and Mooney, DJ (1999). Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 20: 45-53.
45. Lee KY, Rowley, JA, Eiselt, P, Moy, EM, Bouhadir, KH and Mooney DJ (2000). Controlling mechanical and swelling properties of alginatehydrogels independently of cross-linker type and cross-linking density. Macromolecules 33: 4291-4294.
46. Shapiro, L and Cohen, S (1997). Novel alginate sponges for cell culture and transplantation. Biomaterials 18: 583-590.
47. Vandenburgh, H, Shansky, J, Del Tatto, M and Chromiak, J (1999). Organogenesis of skeletal muscle in tissue culture. Methods Mol Med 18: 217-225.
48. Thorrez, L, Vandenburgh, H, Callewaert, N, Mertens, N, Shansky, J, Wang, L et al. (2006). Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants. Mol Ther 14: 442-451.
49. Liao, H and Zhou, GQ (2009). Development and progress of engineering of skeletal muscle tissue. Tissue Eng Part B Rev 15: 319-331.